Earnings summaries and quarterly performance for Paysign.
Executive leadership at Paysign.
Board of directors at Paysign.
Research analysts who have asked questions during Paysign earnings calls.
Gary Prestopino
Barrington Research
4 questions for PAYS
Also covers: AIOT, CARS, CCCS +16 more
Jon Hickman
Ladenburg Thalmann
2 questions for PAYS
Also covers: BLDE, BYRN, CLSK +9 more
Peter Heckmann
D.A. Davidson
2 questions for PAYS
Also covers: ACIW, ALIT, BR +11 more
Alexander Veytsman
B. Riley Securities, Inc.
1 question for PAYS
Jacob Stephan
Lake Street Capital Markets, LLC
1 question for PAYS
Also covers: ALKT, ARLO, CDLX +15 more
Recent press releases and 8-K filings for PAYS.
Paysign Highlights 2024 Financials and Growth Drivers at Southwest IDEAS Conference
PAYS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Paysign reported a market capitalization of just over $300 million, with $58.4 million in annual revenue and $0.07 fully diluted EPS for 2024.
- Trailing 12-month figures show revenue of $74.9 million and fully diluted EPS of $0.13, with adjusted EBITDA at $17.4 million.
- The patient affordability business is a primary growth driver, saving customers over $200 million in claims last year (expected to double this year) and having gross margins around 80%.
- The plasma business, holding about 50% market share, is projected to have flat revenue year-over-year for 2025, with an expected 5% annual growth after Q2 2026, and gross margins of 40-45%.
- Paysign is advancing a new Donor Management System for the blood and plasma collection industry, with FDA approval anticipated by early 2026.
Nov 20, 2025, 3:55 PM
Paysign Highlights 2024 Financials and Growth Drivers
PAYS
Earnings
Guidance Update
New Projects/Investments
- Paysign reported annual revenue of $58.4 million and fully diluted EPS of $0.07 for 2024, with trailing 12-month revenue reaching $74.9 million and EPS of $0.13. The company holds $120 million in total cash and over $200 million in total assets.
- Growth is primarily driven by the patient affordability business, which leverages proprietary "Dynamic Business Rules" technology to save pharmaceutical clients over $200 million in claims last year, with savings projected to double this year. This segment boasts high gross margins of approximately 80%.
- The plasma business, holding about 50% market share, is expected to have flat revenue year-over-year in 2025 due to a significant customer consolidation, but anticipates 5% annual growth after Q2 2026. This segment contributes gross margins of 40-45%.
- A new growth opportunity is expected from the acquired donor management system, Gamma, which is on track for FDA approval in early 2026, following delays from a government shutdown.
Nov 20, 2025, 3:55 PM
Paysign Provides Business Update and Financial Highlights at Conference
PAYS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Paysign reported $74.9 million in trailing 12-month revenue and $0.13 in fully diluted trailing 12-month EPS, reflecting substantial growth from $58.4 million annual revenue and $0.07 annual EPS in 2024.
- The patient affordability business, a primary growth driver, boasts gross margins of approximately 80% and utilizes proprietary "Dynamic Business Rules" technology, which saved customers over $200 million in claims last year. This segment is projected to achieve over $30 million in revenue for 2025.
- Paysign's plasma business maintains about 50% market share and is anticipated to return to approximately 5% annual growth after Q2 2026, following an expected abatement of oversupply by the end of Q1 2026.
- The company is developing a proprietary Donor Management System for the blood and plasma collection industry, with FDA approval expected in early 2026.
Nov 20, 2025, 3:55 PM
Paysign, Inc. Reports Strong Q3 2025 Financial Results and Raises Full-Year Guidance
PAYS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Paysign, Inc. reported record total revenues of $21.60 million for Q3 2025, marking a 41.6% increase from Q3 2024, alongside a 54.2% rise in net income to $2.22 million, resulting in $0.04 diluted earnings per share.
- Adjusted EBITDA grew by 78.1% year-over-year to $5.04 million in Q3 2025.
- Revenue growth was primarily fueled by a 141.9% increase in pharma patient affordability revenue to $7.92 million, ending the quarter with 105 active programs, and a 12.4% increase in plasma revenue to $12.86 million, with 595 plasma centers.
- The company raised its full-year 2025 guidance, now expecting total revenues between $80.5 million and $81.5 million, net income between $7.0 million and $8.0 million (or $0.12 to $0.13 per diluted share), and Adjusted EBITDA between $19.0 million and $20.0 million.
Nov 12, 2025, 10:09 PM
Paysign Announces Q3 2025 Results and Raises Full-Year Guidance
PAYS
Earnings
Guidance Update
New Projects/Investments
- Paysign reported record revenue of $21.6 million in Q3 2025, an increase of 41.6% year over year, with Adjusted EBITDA reaching $5 million, up 78%, and net income rising 54% to $2.2 million.
- The patient affordability business revenue grew 142% to $7.9 million, contributing 36.7% of quarterly revenues, and the company expects to have 125-135 active programs by year-end 2025.
- Paysign raised its full-year 2025 revenue guidance to a range of $80.5 million-$81.5 million, representing 38.7% year-over-year growth at the midpoint, and increased its Adjusted EBITDA outlook to $19 million-$20 million.
- The company opened a new 30,000 sq ft patient support center to expand capacity and is advancing its software as a service engagement platform for the blood and plasma industry, awaiting FDA clearance for its Blood Establishment Computer System (BECCS).
Nov 12, 2025, 10:00 PM
Paysign, Inc. Reports Strong Third Quarter 2025 Financial Results and Raises Full-Year Guidance
PAYS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Paysign, Inc. reported record third quarter 2025 total revenues of $21.60 million, marking a 41.6% increase from the prior year.
- Net income grew 54.2% to $2.22 million, resulting in $0.04 diluted earnings per share, while Adjusted EBITDA increased 78.1% to $5.04 million for the quarter.
- Revenue growth was significantly driven by the pharma patient affordability business, which increased 141.9% to $7.92 million, and the plasma business, which grew 12.4% to $12.86 million.
- The company raised its full-year 2025 guidance, now expecting total revenues between $80.5 million and $81.5 million and net income between $7.0 million and $8.0 million.
Nov 12, 2025, 9:05 PM
Paysign, Inc. Announces Settlement of Stockholder Derivative Actions
PAYS
Legal Proceedings
Management Change
- Paysign, Inc. has entered into a Stipulation and Agreement of Settlement dated November 25, 2024, to resolve stockholder derivative actions alleging breaches of fiduciary duties by individual defendants between March 12, 2019, and September 17, 2020.
- The lawsuits claimed that the company issued materially false and misleading statements, failed to maintain effective IT and financial reporting controls, and delayed its 2019 10-K filing and year-end earnings call.
- Four individual defendants allegedly engaged in insider sales, netting combined proceeds of over $5.7 million during the period.
- As part of the settlement, Paysign will implement and maintain specific corporate governance reforms for five years, including establishing new management-level Information Technology Development and Disclosure Committees.
- A final approval hearing for the settlement is scheduled for November 14, 2025, at 1:00 p.m., at which time the Court will consider approving the terms.
Sep 16, 2025, 1:01 AM
Paysign Opens New Patient Service Support Center
PAYS
New Projects/Investments
Revenue Acceleration/Inflection
- Paysign, Inc. has opened a new 30,000 square foot patient service support center in Henderson, Nevada.
- This expansion quadruples Paysign's support capacity, aiming to bolster its rapidly growing patient affordability business.
- The patient affordability business, identified as a key growth driver, saw its revenues increase by 190% year-over-year in the second quarter of 2025.
- The expansion is a strategic move to meet the rapidly growing demand from pharmaceutical manufacturers, supported by innovations like Paysign's proprietary Dynamic Business Rules solution.
Sep 15, 2025, 12:05 PM
Paysign, Inc. Reports Auditor Change in 8-K Filing
PAYS
Auditor Change
- Paysign, Inc. filed an 8-K report on June 6, 2025, detailing key corporate actions and audit updates.
- Moss Adams LLP resigned as the certified auditor due to its merger with Baker Tilly US, LLP on June 3, 2025, and Baker Tilly has been appointed as the new independent auditor.
- The filing includes an exhibit—a letter from Moss Adams dated June 5, 2025—that confirms unmodified audit opinions for prior financial periods.
Jun 6, 2025, 12:00 AM
PaySign Inc Updates at MicroCap Rodeo Conference
PAYS
New Projects/Investments
M&A
Guidance Update
- CFO Jeff Baker outlined the company’s dual-focus on healthcare payment services in the plasma and patient affordability sectors, emphasizing margin expansion and strong cash flow.
- He detailed significant investments including a recent $16M acquisition of Gamma Innovation to expand software capabilities in the plasma industry, and provided guidance on robust growth in the patient affordability business.
Jun 4, 2025, 8:36 PM
Quarterly earnings call transcripts for Paysign.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more